Vyrex Corporation Awarded Patent on Poison Ivy Protection.LA JOLLA, Calif.--(BUSINESS WIRE)--July 10, 1998--Vyrex Corporation (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on SmallCap:VYRX) today announced that the U.S. Patent and Trademark Office has awarded the company a patent covering a method of desensitizing de·sen·si·tize tr.v. de·sen·si·tized, de·sen·si·tiz·ing, de·sen·si·tiz·es 1. To render insensitive or less sensitive. 2. Immunology To make (an individual) nonreactive or insensitive to an antigen. patients to urushiols, chemicals in plants like poison ivy poison ivy, poison oak, and poison sumac, woody vines and trailing or erect shrubs of the family Anacardiaceae (sumac family), native to North America. , oak and sumac which can cause irritating and potentially serious contact dermatitis and respiratory problems. The method includes administering uncomplexed or loosely-complexed cyclodextrins for oral or topical administration. This is Vyrex's second patent covering this technology. Urushiols are a group of alkylcatechols produced by plants which cause mild to severe allergenic Allergenic A substance capable of causing an allergic reaction. Mentioned in: Echinococcosis responses. These substances are produced by plants found throughout the world, including poison ivy, poison oak and poison sumac. According to Sheldon S. Hendler, Ph.D., M.D, Vyrex Chairman and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. , "Our patent covers a simple, effective method of using the body's own response mechanisms to desensitize de·sen·si·tize v. 1. To render insensitive or less sensitive, as a nerve or tooth. 2. To make an individual nonreactive or insensitive to an antigen. 3. against the painful irritation caused by exposure to urushiols. When used prior to exposure, the skin, mucous membranes and the lungs may be protected." "Skin rashes and lung irritations caused by urushiols are significant problems," added Dr. Hendler. Recently published statistics indicate that last year more than 9 million Americans sought treatment for rashes due to poison ivy and 85 percent of the population is sensitive to urushiols if exposed. Vyrex Corporation, a La Jolla-based biopharmaceutical company, is developing nutraceuticals; antioxidant antioxidant, substance that prevents or slows the breakdown of another substance by oxygen. Synthetic and natural antioxidants are used to slow the deterioration of gasoline and rubber, and such antioxidants as vitamin C (ascorbic acid), butylated hydroxytoluene therapeutics to treat respiratory, degenerative and neurological disorders; and CD-Tagging(tm), an enabling platform for gene and protein discovery. There can be no assurance that the opinions, beliefs or predictions contained in this press release regarding technologies or operations will be realized in whole or in part. Any predictions or representations, written or oral, concerning the information contained herein, or opinions regarding future events are solely forward-looking and actual results may be materially different from predictions. There can be no assurance given as to actual results of future events.
CONTACT: Vyrex Corporation
Carl Lewis, 619/454-4446
|
|
||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion